期刊
JOURNAL OF MOLECULAR STRUCTURE
卷 1240, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.molstruc.2021.130506
关键词
Molecular docking; Molecular dynamics; SARS-CoV-2; Main protease; Ribosomal binding domain; Cryptogamic secondary metabolites
资金
- Council of Science and Industrial Research (CSIR)
- Department of Biotechnology (DBT) [GAP-3439]
The study aims to identify potential inhibitors of SARS-CoV-2 through computational evaluation of cryptogamic secondary metabolites. Some metabolites were found to potentially block the virus's major targets, showing promise as inhibitors.
The unprecedented quick spreading of newly emerged SARS-CoV-2, the virus responsible for causing COVID-19 has put the whole world in vast crisis. Several prophylactic interventions are being performed to discover the effective anti-COVID-19 agent. Thus, the present study aims to identify the cryptogamic secondary metabolites (CSMs) as potent inhibitors of two major targets of SARS-Cov2, namely 3-chymotrypsin-like protease (3CL(Pro)) and receptor-binding domain (RBD) of spike glycoprotein (SGP), by implementing a computational approach. Molecular docking was carried out on Autodock 4.2 software with the 3CL(Pro) (PDB ID:6LU7) and RBD of SGP (PDB ID:6W41) of the virus. Lopinavir and Arbidol were taken as positive controls to compare the efficacy of randomly selected 53 CSMs. The drug-likeness and pharmacokinetics properties of all metabolites were accessed to discern the anti-COVID 19 activity acting well at the physiological conditions. The docking results predicted that Marchantin E and Zeorin would potentially block the catalytic site of 3CL(Pro) with the interaction energy values of -8.42 kcal/mol and 9.04 kcal/mol, respectively. In addition, Usnic acid revealed its ability to combat the interaction of RBD of SGP to angiotensin-converting enzyme-2 in docking analysis. To certify the potent metabolites for both targets of SARS-CoV-2, MD analysis was performed for 100 ns. The results confirmed that Marchantin E could inhibit SARS-CoV-2 3CL(Pro) and RBD of SGP as well as reveals excellent pharmacokinetic properties. The present study suggests that the identified CSMs could be quickly positioned for further experimental validation to propose promising inhibitors of SARS-CoV-2. (C) 2021 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据